对于古典EGFR突变NSCLC的治疗进展正在迅速发展
Kelsey Pan1, Suresh S Ramalingam1
1Department of Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, GA, United States.
对表皮生长因子受体 (EGFR) 突变非小细胞肺癌 (NSCLC) 的精确瘤学显示出有希望的结果,但对氨酸激酶抑制剂 (TKIs) 的耐药性仍然存在. 新的组合策略和针对耐药性的疗法正在推动NSCLC的治疗.
科学领域:
- 在瘤学瘤学.
- 精准医学是一门精准的医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 表皮生长因子受体 (EGFR) 突变非小细胞肺癌 (NSCLC) 在向治疗方面取得了显著进展.
- 氨酸激酶抑制剂 (TKIs) 是标准的,但获得的耐药性仍然是一个主要的临床挑战.
- 最近的试验 (ADAURA,NeoADAURA,LAURA) 在早期和晚期NSCLC阶段确立了 osimertinib.
研究的目的:
- 审查EGFR突变性NSCLC的不断变化的治疗环境.
- 讨论当前的挑战和管理治疗耐药性的未来方向.
- 在早期和转移性环境中突出突出进展.
主要方法:
- 关键临床试验和新兴治疗策略的审查.
- 综合疗法和耐药机制的分析.
- 探索新型药物,如双特异性抗体和抗体与药物联合体.
主要成果:
- 奥西默提尼布是跨NSCLC阶段的标准护理,但关于辅助治疗持续时间和ctDNA导向监测的问题仍然存在.
- 前线组合 (osimertinib + 化疗,amivantamab + lazertinib) 改善了转移EGFR突变NSCLC的结果.
- 新兴的策略针对MET放大和EGFR C797S等耐药机制,以及新型药物类别.
结论:
- 对EGFR突变NSCLC的治疗正在变得越来越个性化,并适应耐药性.
- 最佳的测序和组合策略对于最大化患者益处至关重要.
- 未来的研究重点是克服耐药性,以实现持久的全身和内疾病控制.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
